PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.

@article{Luo2016PETIO,
  title={PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.},
  author={Haiming Luo and Christopher G. England and Stephen A. Graves and Haiyan Sun and Glenn X Liu and Robert Jerry Nickles and Weibo Cai},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2016},
  volume={57 2},
  pages={
          285-90
        }
}
UNLABELLED Lung cancer accounts for 17% of cancer-related deaths worldwide, and most patients present with locally advanced or metastatic disease. Novel PET imaging agents for assessing vascular endothelial growth factor receptor-2 (VEGFR-2) expression can be used for detecting VEGFR-2-positive malignancies and subsequent monitoring of therapeutic response to VEGFR-2-targeted therapies. Here, we report the synthesis and characterization of an antibody-based imaging agent for PET imaging of… CONTINUE READING
1
Twitter Mention

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 35 REFERENCES

PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor.

  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2015
VIEW 1 EXCERPT

Molecular MRI of VEGFR-2 reveals intra-tumor and inter-tumor heterogeneity.

  • American journal of nuclear medicine and molecular imaging
  • 2013
VIEW 1 EXCERPT